Concise Prescribing Info
Gastrointestinal tract spasm.
Dosage/Direction for Use
Adult : PO 10-20 mg tid. IM 10-20 mg 4 times daily for 1-2 days if oral therapy is temporarily impractical.
Dosage Details
Gastrointestinal tract spasm
Adult: 10-20 mg 4 times daily for 1-2 days if oral therapy is temporarily impractical.

Gastrointestinal tract spasm
Adult: 10-20 mg tid.
Child: 6 months to 2 years 5-10 mg 3-4 times daily. Max: 40 mg. >2-12 years 10 mg tid. >12 years Same as adult dose.
May be taken with or without food.
Obstructive diseases of the gastrointestinal tract, severe ulcerative colitis, reflux oesophagitis, unstable cardiovascular status in acute haemorrhage, glaucoma, obstructive uropathy, myasthenia gravis, salmonella dysentery. Infants (<6 months). Lactation.
Special Precautions
Patient with prostatic hypertrophy, coronary artery disease, tachyarrhythmic conditions thyrotoxicosis, congestive heart failure, hypertension, autonomic neuropathy, mild-moderate ulcerative colitis, ileostomy or colostomy, mental illness. Renal and hepatic impairment. Children and elderly. Pregnancy.
Adverse Reactions
Significant: Heat prostration, psychosis or delirium, diarrhoea.
Cardiac disorders: Tachyarrhythmia, palpitations, transient bradycardia.
Eye disorders: Mydriasis, cycloplegia, photophobia, rarely, blurred vision.
Gastrointestinal disorders: Dry mouth with difficulty swallowing and talking, dyspepsia, abdominal distension, abdominal pain, rarely rarely, constipation, nausea, vomiting.
General disorders and admin site conditions: Malaise, fatigue.
Investigations: Decreased lactation.
Metabolism and nutrition disorders: Thirst, rarely, anorexia.
Nervous system disorders: Dizziness, rarely, sedation, headache.
Psychiatric disorders: Nervousness, insomnia, confusion, hallucinations.
Renal and urinary disorders: Rarely, dysuria.
Respiratory, thoracic and mediastinal disorders: Reduced bronchial secretions.
Skin and subcutaneous tissue disorders: Dry skin, rarely, rash.
Patient Counseling Information
This drug may cause dizziness, drowsiness or blurred vision, if affected, do not drive or operate machinery.
Monitor anticholinergic effects (e.g. asthenia, nervousness), urinary output, gastrointestinal symptoms.
Symptoms: Headache, dizziness, blurred vision, nausea, dry mouth, difficulty swallowing, dilated pupils, hot dry skin, CNS stimulation (e.g. convulsion), curare-like action (e.g. neuromuscular weakness, paralysis). Management: Symptomatic treatment. Perform gastric lavage, administration of emetic and activated charcoal to reduce absorption. If necessary, administer sedatives (e.g. short-acting barbiturates, benzodiazepines) for management of overt signs of excitement, and parenteral cholinergic agent as an antidote.
Drug Interactions
May enhance the anticholinergic effect of tiotropium, ipratropium, glycopyrrolate, oxatomide, revefenacin. May enhance ulcerogenic effect of K citrate. Increased serum concentration of thiazide diuretics. May decrease the absorption of nitroglycerin.
Description: Dicycloverine, a tertiary amine antimuscarinic, relieves gastrointestinal smooth muscle spasm by blocking the action of acetylcholine at parasympathetic sites in the smooth muscle, CNS and secretory glands.
Synonym: Dicyclomine.
Onset: 1-2 hours.
Duration: Up to 4 hours.
Absorption: Rapidly and well absorbed from the gastrointestinal tract. Bioavailability: IM injection: Approx 2 times more bioavailable than oral administration. Time to peak plasma concentration: 60-90 minutes (oral).
Distribution: Enters breast milk. Volume of distribution: 3.65 L/kg.
Metabolism: Undergoes extensive metabolism.
Excretion: Via urine (80%; small amounts as unchanged drug), faeces (8%). Elimination half-life: Approx 1.8 hours (initial phase).
Chemical Structure

Click on icon to see table/diagram/image
Store below 25°C. Protect from direct sunlight. Protect from excessive heat.
MIMS Class
ATC Classification
A03AA07 - dicycloverine ; Belongs to the class of synthetic anticholinergics, esters with tertiary amino group. Used in the treatment of functional bowel disorders.
Disclaimer: This information is independently developed by MIMS based on Dicycloverine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in